Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …

Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been
the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this …

Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the
presence of either t (8; 21)(q22; q22) or inv (16)(p13q22)/t (16; 16), is considered good-risk …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults that affects the
myeloid lineage. The recent advances have upgraded our understanding of the cytogenetic …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …

Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene
(KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various …